The reported irreversibly binding NTD inhibitor mechanism of the EPI series, if preclinical activities translate to the clinic and sufficient bioavailability is possible, suggests broad scope AR antagonism in prostate cancers expressing escape and/or truncation mutant; however, poor pharmacokinetics of this template suggest that AR overexpression may be difficult to overcome. Here, AR is linked to prostate carcinoma.